Moderna Talks Offer Hope for Enhanced COVID-19 Vaccine Availability In Europe
Portfolio Pulse from Vandana Singh
European countries are negotiating a new COVID-19 vaccine procurement agreement with Moderna Inc (NASDAQ:MRNA) amid rising coronavirus infections. At least eight EU countries have shown interest in the deal. The potential agreement would provide vaccines until 2026, allowing national health authorities to select vaccine formulations for each season. The price per jab is estimated to be around €25, subject to finalization during negotiations.
September 26, 2023 | 4:31 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Moderna is in talks with European countries for a new COVID-19 vaccine procurement agreement. This could potentially increase Moderna's vaccine sales in Europe, positively impacting its stock price.
The news of Moderna negotiating a new vaccine procurement agreement with European countries is directly relevant to the company. If the deal goes through, it could significantly increase Moderna's vaccine sales in Europe, which would likely have a positive impact on its stock price. The importance of this news is high for investors as it could potentially affect the company's revenues and profitability. The confidence in this analysis is high as the information is directly stated in the news article.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100